Sarepta Gene Therapy Misses in Phase 3; Prospects Now Rely on FDA Flexibility
MedCity News
OCTOBER 31, 2023
Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy fell short of its main Phase 3 goal, but the firm contends the full body of evidence supports expanding the therapy’s label to all patients who have the muscle-wasting disease.
Let's personalize your content